Dostarlimab: From preclinical investigation to drug approval and future directions

Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-cell death protein 1 and its ligand, overexpressed in several tumor types. This interaction leads to the inhibition of T-cell proliferation and their apoptosis and exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now the mainstay of treatment for several advanced stage tumors. Dostarlimab is a novel IgG4 anti-PD-1 antibody which has yielded remarkable results in mismatch-repair deficient endometrial cancer and locally advanced rectal cancer. This product review will illustrate the preclinical development of dostarlimab and its pharmacological characteristics, the clinical trials published so far and the ongoing clinical investigations.

Automated summary

Immune checkpoint blockers (ICB) reverse the immunosuppressive phenotype of cancer cells, allowing the host immune system to generate an immune response against the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which inhibits T-cell proliferation and leads to exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now the main treatment for advanced stage tumors. Dostarlimab, a novel IgG4 anti-PD-1 antibody, has shown remarkable results in certain types of cancer.